mobile.zenopa.com Homepage Homepage
Employment Role Location
Business Sector Advanced  
Phone 01494 818 000
Current Jobs

Territory Manager - UCC
Location: Bucks, Essex

HCP Representative
Location: London

Territory Manager - Sports Medicine
Location: Devon and Cornwall

Urology Sales Specialist
Location: West Midlands

Senior Brand Manager (Maternity Cover)
Location: Cambridge

Sales Specialist
Location: London

Global Planning Partner
Location: London

Skin Health Sales Representative
Location: Peterborough, Cambs, Northants

Territory Manager - Sports Medicine
Location: Western Ireland

Senior Business Unit Manager
Location: Berkshire

Senior Account Executive
Location: Kent

HCP Representative
Location: Scotland

Nurse Advisor
Location: Scottish Highlands

Nurse Advisor
Location: Forth Valley

Sales Specialist - PAS
Location: South East

Invitrogen launches Dynabeads MAX Legionella

Posted on 20/08/2008 in Scientific

Invitrogen has launched its Dynabeads MAX Legionella, which it claims will enable a unique process for targeting and concentrating legionella from environmental water samples.

The provider of essential life science technologies for research, production and diagnostics says the product will provide a rapid and highly reliable sample preparation process, to improve the method used, and result achieved, in detection and quantification of legionella.

A number of strains of the legionella bacteria - most commonly Legionella pneumophila - can cause sickness and death in humans and an estimated 8,000 to 18,000 people are diagnosed with legionellosis in the US each year, according to the Centre for Disease Control.

Jim Janicki, vice-president of the organisation's applied markets, believes that by quickly and reliably isolating only the legionella organism, the new product streamlines the procedures for its surveillance and can potentially change the market.

"Invitrogen's technologies are quickly becoming indispensable for many applications that are essential to preserving public health," he added.

The firm announced earlier in the month it is set to receive products and services for gene over-expression from privately-held biotechnology firm Lentigen.
ADNFCR-1050-ID-18740486-ADNFCR

Other news stories from 20/08/2008

Read more in the Zenopa News Archive

How this news is generated

Joe
Operations Director


Pharmaceutical Sales Jobs | Pharmaceutical Executive Jobs | Pharmaceutical Marketing Jobs | Medical Sales Jobs | Medical Devices Marketing Jobs | Medical Executive Jobs
Dental Sales Jobs | Veterinary Sales Jobs | Scientific Sales Jobs | Consumer Healthcare Sales Jobs | Consumer Healthcare Management Jobs | Medical Writing Jobs
Medical Writer Jobs | Healthcare PR Jobs | Animal Health Sales Jobs

home | our clients | browse news | browse jobs | links | hotel directory | Valid HTML | copyright © 2012 Zenopa Ltd | terms & conditions of use